Aromatase Inhibitors in 2026: Updated Bone-Loss Guidance Collides With a CDK4/6-Inhibitor Combination Renaissance

https://www.medscape.com/c99/p10/aromatase-inhibitors-2026-updated-bone-loss-guidance-2026a1000yai?src= Every oncologist prescribing an aromatase inhibitor already knows the drugs work. What is less consistently translated into practice is how much the fracture-risk conversation has changed. An updated multisociety position statement from the International Osteoporosis Foundation, the Cancer and Bone Society, and five other groups now affirms that fracture risk climbs further with the extended-duration aromatase inhibitor regimens that have become routine, and it delivers a revised treatment algorithm for when to start bone-protective therapy. J Bone Oncol